Advanced search
Publication Cover
Future Medicinal Chemistry Volume 6, 2014 - Issue 11
Submit an article Journal homepage
7,224
Views
7
CrossRef citations to date
0
Altmetric
Perspective

The Essential Roles of Chemistry in High-Throughput Screening Triage

Jayme L Dahlin1 Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN55905, USA;2 Medical Scientist Training Program, Mayo Clinic College of Medicine, Rochester, MN55905, USAView further author information
&
Michael A Walters3 Institute for Therapeutics Discovery & Development, University of Minnesota, Minneapolis, MN55414, USACorrespondence[email protected]
View further author information
Pages 1265-1290 | Published online: 27 Aug 2014

References

  • Frye S , CrosbyM, EdwardsT, JulianoR. US academic drug discovery. Nat. Rev. Drug Discov.10, 409–410 (2011).
  • Gurvich VJ , ByrnSR. NIPTE: a multi-university partnership supporting academic drug development. Drug Discov. Today18 (19–20), 916–921 (2013).
  • Rotella DP . Drug discovery 2012 and beyond. ACS Med. Chem. Lett.3 (3), 172–173 (2012).
  • Tralau-Stewart Cathy J , WyattColin A, KleynDominique E, AyadA. Drug discovery: new models for industry–academic partnerships. Drug Discov. Today14 (1–2), 95–101 (2009).
  • Tralau-Stewart C , LowCMR, MarlinN. UK academic drug discovery. Nat. Rev. Drug Discov.13 (1), 15–16 (2014).
  • Iserson KV , MoskopJC. Triage in medicine, part I: concept, history, and types. Ann. Emerg. Med.49 (3), 275–281 (2007).
  • Moskop JC , IsersonKV. Triage in medicine, part II: underlying values and principles. Ann. Emerg. Med.49 (3), 282–287 (2007).
  • Swamidass S , BittkerJ, BodycombeN, RyderS, ClemonsP. An economic framework to prioritize confirmatory tests after a high-throughput screen. J. Biomol. Screen.15 (6), 680–686 (2010).
  • Bickerton GR , PaoliniGV, BesnardJ, MuresanS, HopkinsAL. Quantifying the chemical beauty of drugs. Nat. Chem.4 (2), 90–98 (2012).
  • Lowe JA III . The role of medicinal chemistry in drug discovery. In: The Art of Drug Synthesis. JohnsonDS, LiJJ (Eds). John Wiley & Sons, NJ, USA (2007).
  • Yang X , ParkerD, WhiteheadLet al. A collaborative hit-to-lead investigation leveraging medicinal chemistry expertise with high throughput library design, synthesis and purification capabilities. Comb. Chem. High Throughput Screen.9, 123–130 (2006).
  • Leeson PD , OpreaTI. Drug-like physicochemical properties. RSC Drug Discov. Ser.13, 35–59 (2012).
  • Leeson PD , SpringthorpeB. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov.6 (11), 881–890 (2007).
  • Gleeson MP , ModiS, BenderAet al. The challenges involved in modeling toxicity data in silico: a review. Curr. Pham Des.18 (9), 1266–1291 (2012).
  • Blum LC , ReymondJ-L. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. J. Am. Chem. Soc.131 (25), 8732–8733 (2009).
  • Irwin JJ , ShoichetBK. ZINC – a free database of commercially available compounds for virtual screening. J. Chem. Inf. Comput. Sci.45 (1), 177–182 (2005).
  • The gold standard for chemical substance information. www.cas.org/content/chemical-substances
  • eMolecules: Linking researchers needs to supplier capabilities. www.emolecules.com
  • Bakken GA , BoehmM, BellASet al. Shaping a screening file for maximal lead discovery efficiency and effectiveness: elimination of molecular redundancy. J. Chem. Inf. Mod.52, 2937–2949 (2012).
  • Baum R . Combinatorial chemistry. Chem. Eng. News Arch.74 (7), 28–73 (1996).
  • Baell JB . Broad coverage of commercially available lead-like screening space with fewer than 350,000 compounds. J. Chem. Inf. Mod.53, 39–55 (2013).
  • Walters WP , NamchukM. A guide to drug discovery: designing screens: how to make your hits a hit. Nat. Rev. Drug Discov.2 (4), 259–266 (2003).
  • Lovering F , BikkerJ, HumbletC. Escape from Flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem.52 (21), 6752–6756 (2009).
  • Walters WP . Going further than Lipinski’s rule in drug design. Exp. Opin. Drug Discov.7 (2), 99–107 (2012).
  • Oprea TI , BologaCG, BoyerSet al. A crowdsourcing evaluation of the NIH chemical probes. Nat. Chem. Biol.5 (7), 441–447 (2009).
  • Lajiness MS , MaggioraGM, ShanmugasundaramV. Assessment of the consistency of medicinal chemists in reviewing sets of compounds. J. Med. Chem.47 (20), 4891–4896 (2004).
  • Kutchukian PS , VasilyevaNY, XuJet al. Inside the mind of a medicinal chemist: the role of human bias in compound prioritization during drug discovery. PLoS ONE7 (11), e48476 (2012).
  • Bologa CG , OpreaTI. Compound collection preparation for virtual screening. Methods Mol. Biol.910, 125–143 (2012).
  • Accelrys: Pipeline Pilot. www.accelrys.com/products/pipeline-pilot/
  • Schrödinger: Small-Molecule Drug Discovery Suite. www.schrodinger.com/smdd/
  • Dewitt SH , CzarnikAW. Combinatorial organic synthesis using Parke-Davis’s diversomer method. Acc. Chem. Res.29 (3), 114–122 (1996).
  • Booth RJ , HodgesJC. Polymer-supported quenching reagents for parallel purification. J. Am. Chem. Soc.119 (21), 4882–4886 (1997).
  • Baell JB , HollowayGA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem.53 (7), 2719–2740 (2010).
  • Erlanson DA . Introduction to fragment-based drug discovery. Top. Curr. Chem.317, 1–32 (2012).
  • Albert JS , BlombergN, BreezeALet al. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca’s drug discovery programmes. Curr. Top. Med. Chem.7 (16), 1600–1629 (2007).
  • Ferenczy GG , KeseruGM. How are fragments optimized? A retrospective analysis of 145 fragment optimizations. J. Med. Chem.56 (6), 2478–2486 (2013).
  • Eitner K , KochU. From fragment screening to potent binders: strategies for fragment-to-lead evolution. Mini Rev. Med. Chem.9 (8), 956–961 (2009).
  • Wildman SA . Approaches to virtual screening and screening library selection. Curr. Pharm. Des.19 (26), 4787–4796 (2013).
  • Scior T , BenderA, TresadernGet al. Recognizing pitfalls in virtual screening: a critical review. J. Chem. Inf. Mod.52 (4), 867–881 (2012).
  • Bleicher KH , BoehmH-J, MuellerK, AlanineAI. A guide to drug discovery: hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov.2 (5), 369–378 (2003).
  • ChEMBL ( 02-09-2014). www.ebi.ac.uk/chembl/
  • Bento AP , GaultonA, HerseyAet al. The ChEMBL bioactivity database: an update. Nucleic Acids Res42 (D1), D1083–D1090 (2014).
  • The PubChem Project. (www.pubchem.ncbi.nlm.nih.gov)
  • Lagalwar S , OrrHT. Regulation of ataxin-1 phosphorylation and its impact on biology. Methods Mol. Biol.1010, 201–209 (2013).
  • Setyawan J , KoideK, DillerTCet al. Inhibition of protein kinases by balanol: specificity within the serine/threonine protein kinase subfamily. Mol. Pharm.56 (2), 370–376 (1999).
  • Akamine P , Madhusudan, Brunton LLet al. Balanol analogues probe specificity determinants and the conformational malleability of the cyclic 3’,5’-adenosine monophosphate-dependent protein kinase catalytic subunit. Biochemistry43, 85–96 (2004).
  • Manning G , WhyteDB, MartinezR, HunterT, SudarsanamS. The protein kinase complement of the human genome. Science298 (5600), 1912–1934 (2002).
  • Yan SF , AsatryanH, LiJ, ZhouY. Novel statistical approach for primary high-throughput screening hit selection. J. Chem. Inf. Mod.45 (6), 1784–1790 (2005).
  • Lessene G , CzabotarPE, SleebsBEet al. Structure-guided design of a selective BCL-XL inhibitor. Nat. Chem. Biol.9, 390–397 (2013).
  • Morwick T , BerryA, BrickwoodJet al. Evolution of the thienopyridine class of inhibitors of IkB kinase-beta: part I: hit-to-lead strategies. J. Med. Chem.49, 2898–2908 (2006).
  • Qian K , WangL, CywinCLet al. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J. Med. Chem.52, 1814–1827 (2009).
  • Vidler LR , FilippakopoulosP, FedorovOet al. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J. Med. Chem.56, 8073–8088 (2013).
  • Keseru GM , MakaraGM. Hit discovery and hit-to-lead approaches. Drug Discov. Today11, 741–748 (2006).
  • Macarron R , BanksMN, BojanicDet al. Impact of high-throughput screening in biomedical research. Nat. Rev. Drug Discov.10, 188–195 (2011).
  • Schonbrunn E , BetziS, AlamRet al. Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases. J. Med. Chem.56 (10), 3768–3782 (2013).
  • Hopkins A , GroomC. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today9 (10), 430–431 (2004).
  • Harper G , PickettSD. Methods for mining HTS data. Drug Discov. Today11 (15–16), 694–699 (2006).
  • Malo N , HanleyJA, CerquozziS, PelletierJ, NadonR. Statistical practice in high-throughput screening data analysis. Nat. Biotech.24 (2), 167–175 (2006).
  • Zhang J , ChungT, OldenburgK. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen.4 (2), 67–73 (1999).
  • Gubler H . Methods for statistical analysis, quality assurance and management of primary high-throughput screening data. In: High-Throughput Screening in Drug Discovery.HüserJ (Ed.). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany (2006).
  • Malo N , HanleyJA, CarlileGet al. Experimental design and statistical methods for improved hit detection in high-throughput screening. J. Biomol. Screen.15 (8), 990–1000 (2010).
  • Makarenkov V , KevorkovD, ZentilliP, GagarinA, MaloN, NadonR. HTS-Corrector: software for the statistical analysis and correction of experimental high-throughput screening data. Bioinformatics22 (11), 1408–1409 (2006).
  • Gunter B , BrideauC, PikounisB, LiawA. Statistical and graphical methods for quality control determination of high-throughput screening data. J. Biomol. Screen.8 (6), 624–633 (2003).
  • Inglese J , AuldDS, JadhavAet al. Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl Acad. Sci. USA103 (31), 11473–11478 (2006).
  • Shapiro AB , WalkupGK, KeatingTA. Correction for interference by test samples in high-throughput assays. J. Biomol. Screen.14 (8), 1008–1016 (2009).
  • Brideau C , GunterB, PikounisB, LiawA. Improved statistical methods for hit selection in high-throughput screening. J. Biomol. Screen.8 (6), 634–647 (2003).
  • Baell JB . Observations on screening-based research and some concerning trends in the literature. Future Med. Chem.2 (10), 1529–1546 (2010).
  • Saubern S , GuhaR, BaellJB. KNIME workflow to assess PAINS filters in SMARTS Format. Comparison of RDKit and Indigo cheminformatics libraries. Mol. Inform.30 (10), 847–850 (2011).
  • Baell JB , FerrinsL, FalkH, NikolakopoulosG. PAINS: Relevance to tool compound discovery and fragment-based screening. Aust. J. Chem.66 (12), 1483–1494 (2013).
  • Dahlin JL , SinvilleR, SolbergJet al. A cell-free fluorometric high-throughput screen for inhibitors of Rtt109-catalyzed histone acetylation. PLoS ONE8 (11), e78877 (2013).
  • Bancos I , BidaJP, TianDet al. High-throughput screening for growth inhibitors using a yeast model of familial paraganglioma. PLoS ONE8 (2), e56827 (2013).
  • Bruns RF , WatsonIA. Rules for identifying potentially reactive or promiscuous compounds. J. Med. Chem.55 (22), 9763–9772 (2012).
  • Tomašić T , MašičLP. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. Exp. Opin. Drug Discov.7 (7), 549–60 (2012).
  • Wang Y , CesenaTI, OhnishiYet al. Small molecule screening identifies regulators of the transcription factor ΔFosB. ACS Chem. Neurosci. 3, 546–556 (2012).
  • Metz JT , HuthJR, HajdukPJ. Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups. J. Comput. Aid. Mol. Des.21 (1–3), 139–144 (2007).
  • Rishton G . Reactive compounds and in vitro false positives in HTS. Drug Discov. Today2, 382–384 (1997).
  • Fliege R , MetzlerM. Electrophilic properties of patulin. N-acetylcysteine and glutathione adducts. Chem. Res. Toxicol.13 (5), 373–381 (2000).
  • Huth JR , SongD, MendozaRRet al. Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance. Chem. Res. Toxicol.20 (12), 1752–1759 (2007).
  • Mirković B , SosičI, GobecS, KosJ. Redox-based inactivation of cysteine cathepsins by compounds containing the 4-aminophenol moiety. PLoS ONE6 (11), e27197 (2011).
  • Johnston PA . Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents-real hits or promiscuous artifacts?Curr. Opin. Chem. Biol.15 (1), 174–182 (2011).
  • Johnston PA , SoaresKM, ShindeSNet al. Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents. Assay Drug Dev. Technol.6 (4), 505–518 (2008).
  • Coan KED , MaltbyDA, BurlingameAL, ShoichetBK. Promiscuous aggregate-based inhibitors promote enzyme unfolding. J. Med. Chem.52 (7), 2067–2075 (2009).
  • Coan KED , ShoichetBK. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J. Am. Chem. Soc.130 (29), 9606–9612 (2008).
  • Feng BY , SimeonovA, JadhavAet al. A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem.50 (10), 2385–2390 (2007).
  • Jadhav A , FerreiraRS, KlumppCet al. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J. Med. Chem.53 (1), 37–51 (2010).
  • Seidler J , McgovernSL, DomanTN, ShoichetBK. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem.46 (21), 4477–4486 (2003).
  • Mcgovern S , HelfandB, FengB. A specific mechanism of nonspecific inhibition. J. Med. Chem.46, 4265–4272 (2003).
  • Mcgovern SL , CaselliE, GrigorieffN, ShoichetBK. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem.45 (8), 1712–1722 (2002).
  • Ryan AJ , GrayNM, LowePN, ChungC-W. Effect of detergent on ‘promiscuous’ inhibitors. J. Med. Chem.46 (16), 3448–3451 (2003).
  • Laplante SR , CarsonR, GillardJet al. Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists. J. Med. Chem.56 (12), 5142–5150 (2013).
  • Huth JR , MendozaR, OlejniczakETet al. ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. J. Am. Chem. Soc.127 (1), 217–224 (2005).
  • Mccallum MM , NandhikondaP, TemmerJJet al. High-throughput identification of promiscuous inhibitors from screening libraries with the use of a thiol-containing fluorescent probe. J. Biomol. Screen.18 (6), 705–713 (2013).
  • Epps DE , TaylorBM. A competitive fluorescence assay to measure the reactivity of compounds. Anal. Biochem.295 (1), 101–106 (2001).
  • Böhme A , ThaensD, PaschkeA, SchüürmannG. Kinetic glutathione chemoassay to quantify thiol reactivity of organic electrophiles--application to alpha, beta-unsaturated ketones, acrylates, and propiolates. Chem. Res. Toxicol.22 (4), 742–750 (2009).
  • Avonto C , Taglialatela-ScafatiO, PollastroFet al. An NMR spectroscopic method to identify and classify thiol-trapping agents: revival of Michael acceptors for drug discovery? Ange Chem. 50 (2), 467–471 (2011).
  • Schebb NH , FaberH, MaulRet al. Analysis of glutathione adducts of patulin by means of liquid chromatography (HPLC) with biochemical detection (BCD) and electrospray ionization tandem mass spectrometry (ESI-MS/MS). Anal. Bioanal. Chem.394 (5), 1361–1373 (2009).
  • Wei C , ChupakL, PhilipT, JohnsonB, GentlesR, DrexlerD. Screening and characterization of reactive compounds with in vitro peptide-trapping and liquid chromatography/high-resolution accurate mass spectrometry. J. Biomol. Screen.19 (2), 297–307 (2014).
  • Falk H , ConnorT, YangHet al. An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets. J. Biomol. Screen.16 (10), 1196–1205 (2011).
  • Schorpp K , RothenaignerI, SalminaEet al. Identification of small-molecule frequent hitters from AlphaScreen high-throughput screens. J. Biomol. Screen., 19 (5), 715–726  (2013).
  • Simeonov A , YasgarA, KlumppCet al. Evaluation of micro-parallel liquid chromatography as a method for HTS-coupled actives verification. Assay Drug Dev. Technol.5 (6), 815–824 (2007).
  • Thorne N , AuldDS, IngleseJ. Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr. Opin. Chem. Biol.14 (3), 315–324 (2010).
  • Auld DS , SouthallNT, JadhavAet al. Characterization of chemical libraries for luciferase inhibitory activity. J. Med. Chem.51 (8), 2372–2386 (2008).
  • Heitman LH , VeldhovenJPDV, ZweemerAM, YeK, BrusseeJ, IjzermanAP. False positives in a reporter gene assay: Identification and synthesis of substituted N-pyridin-2-ylbenzamides as competitive inhibitors of firefly luciferase. J. Med. Chem.51 (15), 4724–4729 (2008).
  • Auld DS , ThorneN, MaguireWF, IngleseJ. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc. Natl Acad. Sci. USA106 (9), 3585–3590 (2009).
  • Auld DS , LovellS, ThorneNet al. Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc. Natl Acad. Sci. USA107 (11), 4878–4883 (2010).
  • Simeonov A , JadhavA, ThomasCJet al. Fluorescence spectroscopic profiling of compound libraries. J. Med. Chem.51 (8), 2363–2371 (2008).
  • Turek-Etienne TC , SmallEC, SohSCet al. Evaluation of fluorescent compound interference in 4 fluorescence polarization assays: 2 kinases, 1 protease, and 1 phosphatase. J. Biomol. Screen.8 (2), 176–184 (2003).
  • Beasley JR , DunnDA, WalkerTL, ParlatoSM, LehrachJM, AuldDS. Evaluation of compound interference in immobilized metal ion affinity-based fluorescence polarization detection with a four million member compound collection. Assay Drug Dev. Technol.1 (3), 455–459 (2003).
  • Imbert P-E , UnterreinerV, SiebertD, GublerH, ParkerC, GabrielD. Recommendations for the reduction of compound artifacts in time-resolved fluorescence resonance energy transfer assays. Assay Drug Dev. Technol.5 (3), 363–372 (2007).
  • Pai JJ , KirkupMP, FrankEA, PachterJA, BryantRW. Compounds capable of generating singlet oxygen represent a source of artifactual data in scintillation proximity assays measuring phosphopeptide binding to SH2 domains. Anal. Biochem.270 (1), 33–40 (1999).
  • Canny SA , CruzY, SouthernMR, GriffinPR. PubChem promiscuity: a web resource for gathering compound promiscuity data from PubChem. Bioinformatics28 (1), 140–141 (2009).
  • Han L , WangY, BryantSH. A survey of across-target bioactivity results of small molecules in PubChem. Bioinformatics25 (17), 2251–2255 (2009).
  • Hu Y , BajorathJ. What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data. AAPS J.15 (3), 808–815 (2013).
  • Prinz H . Simplification traps. J. Chem. Biol.5 (1), 1–4 (2012).
  • Prinz H . Hill coefficients, dose–response curves and allosteric mechanisms. J. Chem. Biol.3 (1), 37–44 (2010).
  • Shoichet BK . Interpreting steep dose–response curves in early inhibitor discovery. J. Med. Chem.49 (25), 7274–7277 (2006).
  • Hattori K , WakabayashiH, TamakiK. Predicting key example compounds in competitors’ patent applications using structural information alone. J. Chem. Inf. Model.48 (1), 135–142 (2008).
  • Muchmore SW , EdmundsJJ, StewartKD, HajdukPJ. Cheminformatic tools for medicinal chemists. J. Med. Chem.53 (13), 4830–4841 (2010).
  • Oprea TI , BologaCG, EdwardsBS, ProssnitzER, SklarLA. Post-high-throughput screening analysis: an empirical compound prioritization scheme. J. Biomol. Screen.10 (5), 419–426 (2005).
  • Duffy BC , ZhuL, DecornezH, KitchenDB. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series. Bioorg. Med. Chem.20 (18), 5324–5342 (2012).
  • Wawer M , BajorathJ. Extraction of structure-activity relationship information from high-throughput screening data. Curr. Med. Chem.16 (31), 4049–4057 (2009).
  • Cox PB , GreggRJ, VasudevanA. Abbott Physicochemical Tiering (APT) – a unified approach to HTS triage. Bioorg. Med. Chem.20 (14), 4564–4573 (2012).
  • Lipinski CA , LombardoF, DominyBW, FeeneyPJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev.23 (1–3), 3–25 (1997).
  • Veber DF , JohnsonSR, ChengH-Y, SmithBR, WardKW, KoppleKD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem.45 (12), 2615–2623 (2002).
  • Baell J , CongreveM, LeesonP, Abad-ZapateroC. Ask the experts: past, present and future of the rule of five. Future Med. Chem.5 (7), 745–752 (2013).
  • Hopkins AL , KeserueGM, LeesonPD, ReesDC, ReynoldsCH. The role of ligand efficiency metrics in drug discovery. Nat. Rev. Drug Discov.13 (2), 105–121 (2014).
  • Freeman-Cook KD , HoffmanRL, JohnsonTW. Lipophilic efficiency: the most important efficiency metric in medicinal chemistry. Future Med. Chem.5 (2), 113–115 (2013).
  • Abad-Zapatero C . Ligand efficiency indices for effective drug discovery. Exp. Opin. Drug Discov.2 (4), 469–488 (2007).
  • Abad-Zapatero C , BlasiD. Ligand efficiency indices (LEIs): more than a simple efficiency yardstick. Mol. Inform.30 (2–3), 122–132 (2011).
  • Abad-Zapatero C , MetzJT. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today10 (7), 464–469 (2005).
  • Šink R , GobecS, PecarS. False positives in the early stages of drug discovery. Curr. Med. Chem.17, 4231–4255 (2010).
  • Cumming JG , DavisAM, MuresanS, HaeberleinM, ChenH. Chemical predictive modelling to improve compound quality. Nat. Rev. Drug Discov.12 (12), 948–962 (2013).
  • Neuwald A , LandsmanD. GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem. Sci.22, 154–155 (1997).
  • Wager TT , HouX, VerhoestPR, VillalobosA. Moving beyond rules: the development of a Central Nervous System Multiparameter Optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci.1 (6), 435–449 (2010).
  • Zhu T , CaoS, SuP-Cet al. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J. Med. Chem.56 (17), 6560–6572 (2013).
  • Tanrikulu Y , KrugerB, ProschakE. The holistic integration of virtual screening in drug discovery. Drug Discov. Today18 (7–8), 358–364 (2013).
  • Lagorce D , MaupetitJ, BaellJet al. The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections. Bioinformatics27 (14), 2018–2020 (2011).
  • Park J-G , KahnJN, TumerNE, PangY-P. Chemical structure of Retro-2, a compound that protects cells against ribosome-inactivating proteins. Sci. Rep.2, 631 (2012).
  • Kozikowski BA , BurtTM, TireyDAet al. The effect of room-temperature storage on the stability of compounds in DMSO. J. Biomol. Screen.8 (2), 205–209 (2003).
  • Kozikowski BA , BurtTM, TireyDAet al. The effect of freeze/thaw cycles on the stability of compounds in DMSO. J. Biomol. Screen.8 (2), 210–215 (2003).
  • Blaxill Z , Holland-CrimminS, LifelyR. Stability through the ages: the GSK experience. J. Biomol. Screen.14 (5), 547–556 (2009).
  • Ellson R , StearnsR, MutzMet al. In situ DMSO hydration measurements of HTS compound libraries. Comb. Chem. High Throughput Screen.8 (6), 489–498 (2005).
  • Engeloch C , SchopferU, MuckenschnabelIet al. Stability of screening compounds in wet DMSO. J. Biomol. Screen.13 (10), 999–1006 (2008).
  • Matson SL , ChatterjeeM, StockDAet al. Best practices in compound management for preserving compound integrity and accurately providing samples for assays. J. Biomol. Screen.14 (5), 476–484 (2009).
  • Kenseth JR , ColdironSJ. High-throughput characterization and quality control of small-molecule combinatorial libraries. Curr. Opin. Chem. Biol.8 (4), 418–423 (2004).
  • Wipf P , ArnoldD, CarterKet al. A case study from the chemistry core of the Pittsburgh Molecular Library Screening Center: the Polo-like kinase polo-box domain (Plk1-PBD). Curr. Topics Med. Chem.9 (13), 1194–1205 (2009).
  • Hermann JC , ChenY, WartchowCet al. Metal impurities cause false positives in high-throughput screening campaigns. ACS Med. Chem. Lett.4 (2), 197–200 (2013).
  • Tarzia G , AntoniettiF, DurantiAet al. Identification of a bioactive impurity in a commercial sample of 6-methyl-2-p-tolylaminobenzo[d][1,3]oxazin-4-one (URB754). Ann. Chim.97 (9), 887–894 (2007).
  • Guntupalli S , RayUK, MuraliNet al. Identification, isolation and characterization of process related impurities in ezetimibe. J. Pharm. Biomed. Anal.88, 385–390 (2014).
  • Liu M , WangJ, WuXet al. HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424). J. Pharm. Biomed. Anal.89, 34–41 (2014).
  • Verbeken M , WynendaeleE, LefebvreRA, GoossensE, SpiegeleerBD. The influence of peptide impurity profiles on functional tissue-organ bath response: the 11-mer peptide INSL6[151–161] case. Anal. Biochem.421 (2), 547–555 (2012).
  • Dotterer SK , ForbesRA, HammillCL. Impact of metal-induced degradation on the determination of pharmaceutical compound purity and a strategy for mitigation. J. Pharm. Biomed. Anal.54 (5), 987–994 (2011).
  • Jaki BU , FrazblauSG, ChadwickLRet al. Purity–activity relationships of natural products: the case of anti-TB active ursolic acid. J. Nat. Prod.71, 1742–1748 (2008).
  • Ekins S , FreundlichJS, HobrathJV, LucileWhite E, ReynoldsRC. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. Pharm. Res.31 (2), 414–435 (2014).
  • Zhang L , WangX, FengJ, JiaY, XuF, XuW. Discovery of novel vascular endothelial growth factor receptor 2 inhibitors: a virtual screening approach. Chem. Biol. Drug Des.80 (6), 893–901 (2012).
  • Zhang X-F , TanM, ChhabraM, DaiY-C, MellerJ, JiangX. Inhibition of histo-blood group antigen binding as a novel strategy to block Norovirus infections. PLoS ONE8 (7), e69379 (2013).
  • Zhu P , PengH, NiN, WangB, LiM. Novel AI-2 quorum sensing inhibitors in Vibrio harveyi identified through structure-based virtual screening. Bioorg. Med. Chem. Lett.22 (20), 6413–6417 (2012).
  • Zhuang C , NarayanapillaiS, ZhangW, ShamYY, XingC. Rapid identification of Keap1-Nrf2 small-molecule inhibitors through structure-based virtual screening and hit-based substructure search. J. Med. Chem.57 (3), 1121–1126 (2014).
  • Liang Z , DingX, AiJet al. Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay. Org. Biomol. Chem.10 (2), 421–430 (2012).
  • Mukherjee P , DesaiP, RossL, WhiteEL, AveryMA. Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits. Bioorg. Med. Chem.16 (7), 4138–4149 (2008).
  • Chen L , ChenS, GuiC, ShenJ, ShenX, JiangH. Discovering severe acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual screening, surface plasmon resonance, and fluorescence resonance energy transfer assays. J. Biomol. Screen.11 (8), 915–921 (2006).
  • Han C , ZhangJ, ChenL, ChenK, ShenX, JiangH. Discovery of Helicobacter pylori shikimate kinase inhibitors: bioassay and molecular modeling. Bioorg. Med Chem.15 (2), 656–662 (2007).
  • Schepetkin IA , KhlebnikovAI, KirpotinaLN, QuinnMT. Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput Screening. J. Med. Chem.49 (17), 5232–5244 (2006).
  • Xie Y , LiuY, GongGet al. Discovery of a novel submicromolar inhibitor of the lymphoid specific tyrosine phosphatase. Bioorg. Med. Chem. Lett.18 (9), 2840–2844 (2008).
  • Xu F , ZhangL, JiaYet al. Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Eur. J. Med. Chem.69, 191–200 (2013).
  • Qin J , XieP, VentocillaCet al. Identification of a novel family of BRAFV600E inhibitors. J. Med. Chem.55, 5220–5230 (2012).
  • Ge Y , KaziA, MarsilioFet al. Discovery and synthesis of hydronaphthoquinones as novel proteasome inhibitors. J. Med. Chem.55 (5), 1978–1998 (2012).
  • Soares KM , BlackmonN, ShunTYet al. Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments. Assay Drug Dev. Technol.8 (2), 152–174 (2010).
  • Kilgore JA , DuX, MelitoLet al. Identification of DNMT1 selective antagonists using a novel scintillation proximity assay. J. Biol. Chem.288 (27), 19673–19684 (2013).
  • Nagarajan S , SkoufiasDA, KozielskiF, PaeAN. Receptor–ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors. J. Med. Chem.55 (6), 2561–2573 (2012).
  • Park I-H , LiC. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation. J. Mol. Recognit.24, 254–265 (2011).
  • Xu X , KasembeliMM, JiangX, TweardyBJ, TweardyDJ. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS ONE4 (3), e4783 (2009).
  • Gilson MK , GeorgG, WangS. Digital chemistry in the Journal of Medicinal Chemistry. J. Med. Chem.57 (4), 1137–1137 (2014).
  • Kalgutkar AS , DalvieDK. Drug discovery for a new generation of covalent drugs. Exp. Opin. Drug Discov.7 (7), 561–581 (2012).
  • Vince R . A brief history of the development of Ziagen. Chemtracts-Org. Chem.21 (4), 127–134 (2008).
  • Dosa PI , GeorgGI, GurvichVJ, HawkinsonJE, WaltersMA, WongHL. From HTS to Phase I: The Institute for Therapeutics Discovery and Development at the University of Minnesota. Comb. Chem. High Throughput Screen.17 (3), 231–240. (2014).
  • CAS. www.cas.org

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.